Literature DB >> 24772302

En bloc vascular resection for the treatment of borderline resectable pancreatic head carcinoma.

Hirohisa Kitagawa1, Hidehiro Tajima1, Hisatoshi Nakagawara1, Isamu Makino1, Tomoharu Miyashita1, Masatoshi Shoji1, Shinichi Nakanuma1, Norihiro Hayashi1, Hiroyuki Takamura1, Tetsuo Ohta1, Hiroshi Ohtake2.   

Abstract

Borderline resectable (BR) pancreatic head carcinoma (PhC) is an advanced disease, presenting with infiltration of major vessels. Major vascular resection (VR), particularly arterial resection, to achieve microscopic no residual tumor (R0) is a controversial approach, due to the potential complications. In this study, we aimed to clarify the benefit of en bloc R0 resection with VR for PhC by retrospectively evaluating 78 PhC patients who underwent pancreatoduodenectomy at our institute. The patients were divided into 4 groups as follows: R, resectable (n=20); BR-V, BR involving the superior mesenteric vein or portal vein (PV) (n=28); BR-SMA, BR involving the superior mesenteric artery (n=21); and BR-HA, BR involving the hepatic artery (n=9). In total, 65 patients underwent VR, with 63, 21 and 9 patients undergoing PV, SMA and HA resection, respectively. The R0 rates were as follows: R group, 85%; BR-V, 82%; BR-SMA, 71%; and BR-HA, 33%. The median survival time and 5-year survival rate for R0 resection were 31 months and 25% in the R group, 22 months and 28% in the BR-V group, 17 months and 27% in the BR-SMA group and 10 months and 0% in the BR-HA group, respectively. The prognosis was comparable among the BR-V, BR-SMA and R groups, but was significantly poorer in the BR-HA group. In total, 5 patients (6.4%) died perioperatively (4 from postoperative hemorrhage and 1 from suffocation due to failure of expectoration, without pneumonia or asthma). Of the 4 patients who succumbed to hemorrhage, 3 had undergone arterial resection. Therefore, en bloc resection with major VR for R0 may be suitable for BR-V and BR-SMA PhC patients.

Entities:  

Keywords:  borderline resectable; en bloc arterial resection; meso-pancreatoduodenum; pancreatic head carcinoma; superior mesenteric artery

Year:  2014        PMID: 24772302      PMCID: PMC3999123          DOI: 10.3892/mco.2014.266

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  25 in total

Review 1.  Resection margins and R1 rates in pancreatic cancer--are we there yet?

Authors:  C S Verbeke
Journal:  Histopathology       Date:  2007-12-13       Impact factor: 5.087

2.  Most pancreatic cancer resections are R1 resections.

Authors:  Irene Esposito; Jörg Kleeff; Frank Bergmann; Caroline Reiser; Esther Herpel; Helmut Friess; Peter Schirmacher; Markus W Büchler
Journal:  Ann Surg Oncol       Date:  2008-03-20       Impact factor: 5.344

3.  MDCT findings of extrapancreatic nerve plexus invasion by pancreas head carcinoma: correlation with en bloc pathological specimens and diagnostic accuracy.

Authors:  Kentaro Mochizuki; Toshifumi Gabata; Kazuto Kozaka; Yuki Hattori; Yoh Zen; Hirohisa Kitagawa; Masato Kayahara; Tetsuo Ohta; Osamu Matsui
Journal:  Eur Radiol       Date:  2010-02-10       Impact factor: 5.315

4.  Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection.

Authors:  Akimasa Nakao; Shin Takeda; Mitsuru Sakai; Tetsuya Kaneko; Soichiro Inoue; Hiroyuki Sugimoto; Naohito Kanazumi
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

5.  Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Authors:  Ioannis T Konstantinidis; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers; David P Ryan; Jennifer A Wargo; Keith D Lillemoe; Cristina R Ferrone
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

6.  Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma.

Authors:  Jennifer L Gnerlich; Samuel R Luka; Anjali D Deshpande; Bernard J Dubray; Joshua S Weir; Danielle H Carpenter; Elizabeth M Brunt; Steven M Strasberg; William G Hawkins; David C Linehan
Journal:  Arch Surg       Date:  2012-08

7.  Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion.

Authors:  M Kayahara; T Nagakawa; K Ueno; T Ohta; Y Tsukioka; I Miyazaki
Journal:  Surgery       Date:  1995-06       Impact factor: 3.982

8.  Clinicopathological study of pancreatic carcinoma with particular reference to the invasion of the extrapancreatic neural plexus.

Authors:  M Kayahara; T Nagakawa; I Konishi; K Ueno; T Ohta; I Miyazaki
Journal:  Int J Pancreatol       Date:  1991-10

9.  Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin.

Authors:  Fiona Campbell; Richard A Smith; Philip Whelan; Robert Sutton; Michael Raraty; John P Neoptolemos; Paula Ghaneh
Journal:  Histopathology       Date:  2009-09       Impact factor: 5.087

10.  The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials.

Authors:  J Gaedcke; B Gunawan; M Grade; R Szöke; T Liersch; H Becker; B M Ghadimi
Journal:  Langenbecks Arch Surg       Date:  2009-05-06       Impact factor: 3.445

View more
  6 in total

1.  A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer.

Authors:  Hidehiro Tajima; Isamu Makino; Ryosuke Gabata; Mitsuyoshi Okazaki; Yoshinao Ohbatake; Hiroyuki Shimbashi; Shinich Nakanuma; Hiroto Saitoh; Mari Shimada; Takahisa Yamaguchi; Koichi Okamoto; Hideki Moriyama; Jun Kinoshita; Keishi Nakamura; Tomoharu Miyashita; Itasu Ninomiya; Sachio Fushida; Hiroko Ikeda; Tetsuo Ohta
Journal:  Mol Clin Oncol       Date:  2020-12-14

2.  Systematic review of the mesopancreas: concept and clinical implications.

Authors:  J M Ramia; R De-la-Plaza; A Manuel-Vazquez; A Lopez-Marcano; R Morales
Journal:  Clin Transl Oncol       Date:  2018-04-19       Impact factor: 3.405

3.  Location of the meso-pancreatoduodenum as a regional lymphatic basin for pancreatic head carcinoma.

Authors:  Hirofumi Terakawa; Hirohisa Kitagawa; Isamu Makino; Hironori Hayashi; Katsunobu Oyama; Hisatoshi Nakagawara; Tomoharu Miyashita; Hidehiro Tajima; Hiroyuki Takamura; Sachio Fushida; Noriyuki Ozaki; Tetsuo Ohta
Journal:  Oncol Lett       Date:  2017-05-09       Impact factor: 2.967

4.  Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.

Authors:  Hidehiro Tajima; Isamu Makino; Yoshinao Ohbatake; Shinichi Nakanuma; Hironori Hayashi; Hisatoshi Nakagawara; Tomoharu Miyashita; Hiroyuki Takamura; Tetsuo Ohta
Journal:  Oncol Lett       Date:  2017-04-07       Impact factor: 2.967

5.  Prognostic analysis of pancreatic carcinoma with portal system invasion following curative resection.

Authors:  Jing Wang; Shao-Cheng Lyu; Lin Zhou; Han Wang; Fei Pan; Tao Jiang; Ren Lang; Qiang He
Journal:  Gland Surg       Date:  2021-01

6.  Hind right approach pancreaticoduodenectomy: from skill to indications.

Authors:  Stefan Georgescu; Corina Ursulescu; Valentin Titus Grigorean; Cristian Lupascu
Journal:  Gastroenterol Res Pract       Date:  2014-08-10       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.